Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Drug-Induced Cardiotoxicity 2023
share announcement

Drug-Induced Cardiotoxicity 2023

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 7167

Special Issue Editor

Dr. Jacek Bil

E-Mail Website
Guest Editor
Department of Cardiology, National Medical Institute of the Ministry of Interior and Administration, Woloska 137 Street, 02-507 Warsaw, Poland
Interests: coronary stents; cardiology; coronary artery disease; INOCA; MINOCA; acetylcholine; percutaneous coronary intervention; obesity, GLP1 analogues; coronary bifurcations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, the cardiotoxicity of cancer treatments has been a topic of growing interest, and an entirely new branch has developed, i.e., cardio-oncology. In 2020, the European Society of Cardiology issued the first cardio-oncology guidelines. Nevertheless, many aspects of cancer drug-induced cardiovascular diseases remain not fully elucidated.

Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only due to myocyte toxicity. However, not all vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In recent decades, it has been revealed that myocardial ischemia may occur because of structural or functional dysfunction in the complex network of coronary microcirculation vessels.

We invite authors to submit original studies, reviews, meta-analyses, and case reports focused on drug-induced cardiotoxicity showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection. We are soliciting not only human studies but animal and molecular studies as well.

Dr. Jacek Bil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiooncology
  • heart failure
  • microcirculation
  • treatment complications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 6144 KiB  
Article
Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
by Kevin Agostinucci, Marianne K. O. Grant, Wongel Melaku, Chandini Nair and Beshay N. Zordoky
Pharmaceuticals 2023, 16(3), 391; https://doi.org/10.3390/ph16030391 - 4 Mar 2023
Cited by 8 | Viewed by 2961
Abstract
Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported. We identified the sexual dimorphic effects of isoproterenol in mice pre-exposed to doxorubicin. [...] Read more.
Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported. We identified the sexual dimorphic effects of isoproterenol in mice pre-exposed to doxorubicin. Male and female intact or gonadectomized C57BL/6N mice underwent five weekly intraperitoneal injections of 4 mg/kg doxorubicin followed by a five-week recovery period. Fourteen days of subcutaneous isoproterenol injections (10 mg/kg/day) were administered after the recovery period. Echocardiography was used to assess heart function one and five weeks after the last doxorubicin injection and on the fourteenth day of isoproterenol treatment. Thereafter, mice were euthanized, and the hearts were weighed and processed for histopathology and gene expression analysis. Doxorubicin did not produce overt cardiac dysfunction in male or female mice before starting isoproterenol treatment. The chronotropic response to a single isoproterenol injection was blunted by doxorubicin, but the inotropic response was maintained in both males and females. Pre-exposure to doxorubicin caused cardiac atrophy in both control and isoproterenol-treated male mice but not in female mice. Counterintuitively, pre-exposure to doxorubicin abrogated isoproterenol-induced cardiac fibrosis. However, there were no sex differences in the expression of markers of pathological hypertrophy, fibrosis, or inflammation. Gonadectomy did not reverse the sexually dimorphic effects of doxorubicin. Additionally, pre-exposure to doxorubicin abrogated the hypertrophic response to isoproterenol in castrated male mice but not in ovariectomized female mice. Therefore, pre-exposure to doxorubicin caused male-specific cardiac atrophy that persisted after isoproterenol treatment, which could not be prevented by gonadectomy. Full article
(This article belongs to the Special Issue Drug-Induced Cardiotoxicity 2023)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 2567 KiB  
Review
Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy
by Monu Kumar Kashyap, Shubhada V. Mangrulkar, Sapana Kushwaha, Akash Ved, Mayur B. Kale, Nitu L. Wankhede, Brijesh G. Taksande, Aman B. Upaganlawar, Milind J. Umekar, Sushruta Koppula and Spandana Rajendra Kopalli
Pharmaceuticals 2023, 16(10), 1441; https://doi.org/10.3390/ph16101441 - 11 Oct 2023
Cited by 4 | Viewed by 3624
Abstract
Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. [...] Read more.
Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF/Ras/Raf/MEK/ERK, and the PI3/ERK/AMPK/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy. Full article
(This article belongs to the Special Issue Drug-Induced Cardiotoxicity 2023)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop